Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alexander, Virtanen"'
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The therapeutic IgG1 anti-CD20 antibody, rituximab (RTX), has greatly improved prognosis of many B-cell malignancies. Despite its success, resistance has been reported and detailed knowledge of RTX mechanisms are lacking. Compleme
Externí odkaz:
https://doaj.org/article/dbbbec6a1c43408eacd57d446e79377a
Background The therapeutic IgG1 anti-CD20 antibody, rituximab (RTX), has greatly improved prognosis of many B-cell malignancies. Despite its success, resistance has been reported and detailed knowledge of RTX mechanisms are lacking. Complement-depend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293bc47865f011c5122aec512fec9a8a
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-483791
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-483791
Monoclonal antibodies (mAbs) have revolutionized clinical medicine, especially in the field of cancer immunotherapy. The challenge now is to improve the response rates, as immunotherapy still fails for many patients. Strategies to enhance tumor cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4757725434d75b47f292e670e4a435d8
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-445481
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-445481
Monoclonal antibodies (mAb) have revolutionized clinical medicine, especially in the field of cancer immunotherapy. The challenge now is to improve the response rates in the patients, as immunotherapy still fails for many patients. Strategies to enha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79ea448068d8f5deffa54d1096347c7b
https://doi.org/10.1101/2020.07.01.181800
https://doi.org/10.1101/2020.07.01.181800
Publikováno v:
European journal of immunology. 26(12)
Two alternative forms of IgM heavy-chain mRNA are produced from a common precursor mRNA as a result of competition between cleavage/poly(A) addition at the upstream (secretory) poly(A) site and cleavage/poly(A) addition at the downstream (membrane) p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72299838f1a4e4967fdd5892a3b1c1db
https://pubmed.ncbi.nlm.nih.gov/8977316
https://pubmed.ncbi.nlm.nih.gov/8977316